Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study
Abstract Background The association between multiple sclerosis (MS) and cancer has long been investigated with conflicting results. Several reports suggest an increased cancer risk among MS patients treated with immunosuppressant (IS) drugs. Methods We performed a cohort study including MS patients...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-08-01
|
Series: | BMC Neurology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12883-017-0932-0 |
id |
doaj-78fbbec990864151be815844fda57273 |
---|---|
record_format |
Article |
spelling |
doaj-78fbbec990864151be815844fda572732020-11-24T21:48:17ZengBMCBMC Neurology1471-23772017-08-011711610.1186/s12883-017-0932-0Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort studyPaolo Ragonese0Paolo Aridon1Giulia Vazzoler2Maria Antonietta Mazzola3Vincenzina Lo Re4Marianna Lo Re5Sabrina Realmuto6Simona Alessi7Marco D’Amelio8Giovanni Savettieri9Giuseppe Salemi10Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche (Department of Experimental Biomedicine and Clinical Neurosciences), Università degli Studi di PalermoDipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche (Department of Experimental Biomedicine and Clinical Neurosciences), Università degli Studi di PalermoDipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche (Department of Experimental Biomedicine and Clinical Neurosciences), Università degli Studi di PalermoDipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche (Department of Experimental Biomedicine and Clinical Neurosciences), Università degli Studi di PalermoDipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche (Department of Experimental Biomedicine and Clinical Neurosciences), Università degli Studi di PalermoDipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche (Department of Experimental Biomedicine and Clinical Neurosciences), Università degli Studi di PalermoDipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche (Department of Experimental Biomedicine and Clinical Neurosciences), Università degli Studi di PalermoDipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche (Department of Experimental Biomedicine and Clinical Neurosciences), Università degli Studi di PalermoDipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche (Department of Experimental Biomedicine and Clinical Neurosciences), Università degli Studi di PalermoDipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche (Department of Experimental Biomedicine and Clinical Neurosciences), Università degli Studi di PalermoDipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche (Department of Experimental Biomedicine and Clinical Neurosciences), Università degli Studi di PalermoAbstract Background The association between multiple sclerosis (MS) and cancer has long been investigated with conflicting results. Several reports suggest an increased cancer risk among MS patients treated with immunosuppressant (IS) drugs. Methods We performed a cohort study including MS patients recruited at the Neurological Department of the University of Palermo. Mean follow-up period was ten years for the whole cohort. We calculated cancer incidence among patients treated with IS. Incidence rates were compared in the cohort by calculating the relative risk according to length and dose of exposure to IS. Cancer incidence among MS patients was compared to cancer incidence in the general population of Sicily in similar age groups. Results On an overall cohort of 531 MS patients (346 women and 185 men) exposed to IS, we estimated a crude incidence rate for cancer of 2.26% (2.02% in women, 2.7% in men). Cancer risk was higher compared to rates observed among an equal number of patients not exposed to IS, and to the risk in the general population in Sicily at similar age groups (adjusted HR: 11.05; CI 1.67–73.3; p = 0.013). Conclusion The present study showed a higher cancer risk in MS patients associated only to previous IS exposure. Studies on long-term outcomes are essential to evaluate the possibility that treatment options that need to be considered for a long time-period may modify risk for life threatening diseases.http://link.springer.com/article/10.1186/s12883-017-0932-0Multiple sclerosisCancerCohort studyImmunosuppressantTreatment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Paolo Ragonese Paolo Aridon Giulia Vazzoler Maria Antonietta Mazzola Vincenzina Lo Re Marianna Lo Re Sabrina Realmuto Simona Alessi Marco D’Amelio Giovanni Savettieri Giuseppe Salemi |
spellingShingle |
Paolo Ragonese Paolo Aridon Giulia Vazzoler Maria Antonietta Mazzola Vincenzina Lo Re Marianna Lo Re Sabrina Realmuto Simona Alessi Marco D’Amelio Giovanni Savettieri Giuseppe Salemi Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study BMC Neurology Multiple sclerosis Cancer Cohort study Immunosuppressant Treatment |
author_facet |
Paolo Ragonese Paolo Aridon Giulia Vazzoler Maria Antonietta Mazzola Vincenzina Lo Re Marianna Lo Re Sabrina Realmuto Simona Alessi Marco D’Amelio Giovanni Savettieri Giuseppe Salemi |
author_sort |
Paolo Ragonese |
title |
Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study |
title_short |
Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study |
title_full |
Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study |
title_fullStr |
Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study |
title_full_unstemmed |
Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study |
title_sort |
association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study |
publisher |
BMC |
series |
BMC Neurology |
issn |
1471-2377 |
publishDate |
2017-08-01 |
description |
Abstract Background The association between multiple sclerosis (MS) and cancer has long been investigated with conflicting results. Several reports suggest an increased cancer risk among MS patients treated with immunosuppressant (IS) drugs. Methods We performed a cohort study including MS patients recruited at the Neurological Department of the University of Palermo. Mean follow-up period was ten years for the whole cohort. We calculated cancer incidence among patients treated with IS. Incidence rates were compared in the cohort by calculating the relative risk according to length and dose of exposure to IS. Cancer incidence among MS patients was compared to cancer incidence in the general population of Sicily in similar age groups. Results On an overall cohort of 531 MS patients (346 women and 185 men) exposed to IS, we estimated a crude incidence rate for cancer of 2.26% (2.02% in women, 2.7% in men). Cancer risk was higher compared to rates observed among an equal number of patients not exposed to IS, and to the risk in the general population in Sicily at similar age groups (adjusted HR: 11.05; CI 1.67–73.3; p = 0.013). Conclusion The present study showed a higher cancer risk in MS patients associated only to previous IS exposure. Studies on long-term outcomes are essential to evaluate the possibility that treatment options that need to be considered for a long time-period may modify risk for life threatening diseases. |
topic |
Multiple sclerosis Cancer Cohort study Immunosuppressant Treatment |
url |
http://link.springer.com/article/10.1186/s12883-017-0932-0 |
work_keys_str_mv |
AT paoloragonese associationbetweenmultiplesclerosiscancerriskandimmunosuppressanttreatmentacohortstudy AT paoloaridon associationbetweenmultiplesclerosiscancerriskandimmunosuppressanttreatmentacohortstudy AT giuliavazzoler associationbetweenmultiplesclerosiscancerriskandimmunosuppressanttreatmentacohortstudy AT mariaantoniettamazzola associationbetweenmultiplesclerosiscancerriskandimmunosuppressanttreatmentacohortstudy AT vincenzinalore associationbetweenmultiplesclerosiscancerriskandimmunosuppressanttreatmentacohortstudy AT mariannalore associationbetweenmultiplesclerosiscancerriskandimmunosuppressanttreatmentacohortstudy AT sabrinarealmuto associationbetweenmultiplesclerosiscancerriskandimmunosuppressanttreatmentacohortstudy AT simonaalessi associationbetweenmultiplesclerosiscancerriskandimmunosuppressanttreatmentacohortstudy AT marcodamelio associationbetweenmultiplesclerosiscancerriskandimmunosuppressanttreatmentacohortstudy AT giovannisavettieri associationbetweenmultiplesclerosiscancerriskandimmunosuppressanttreatmentacohortstudy AT giuseppesalemi associationbetweenmultiplesclerosiscancerriskandimmunosuppressanttreatmentacohortstudy |
_version_ |
1725893054934548480 |